Stockreport

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance...

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targe [Read more]